News Archive

With new wearable devices and apps entering the market every day, many clinicians have seen a proliferation of patient-generated data.

Actus Therapeutics, a privately held portfolio company of Asklepios BioPharmaceutical, Inc. (AskBio), recently announced the dosing of the first patient in a phase I/II clinical study of ACTUS-101 in patients with Pompe disease. Pompe disease is a serious disease associated with high morbidity and often leads to premature death. There are variable rates of disease progression and different ages of onset characterized as infantile-onset and late-onset disease.

Researchers hope to develop a test that could detect early changes in blood flow to the heart.

Patients who were moved between hospitals before receiving endovascular therapy were more likely to experience adverse clinical outcomes.

A DCRI team has begun enrollment for a clinical trial investigating the optimal evaluation strategies for people with symptoms of coronary artery disease. PRECISE, or Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization, will enroll 2,100 patients across 100 sites in the U.S, Canada, and Europe. The trial is led by the DCRI’s Pamela Douglas, MD.

A special report published this week in the journal Circulation calls for urgent action to counter the toll from heart disease, currently the leading cause of death in the United States and worldwide. The “Presidential Advisory,” which introduces a joint initiative on value in cardiovascular care between the American Heart Association (AHA) and the Duke Margolis Center for Health Policy, includes former FDA Commissioners Robert M. Califf, MD (DCRI founder and director of Duke Forge) and Mark McClellan, MD, PhD (director, Duke Margolis Center) as co-authors.

The Kevin L. Thomas, MD Scholarship will be awarded to high school students interested in medical careers.

Jessilyn Dunn, PhD, is a faculty member in Duke’s Departments of Biomedical Engineering; Biostatistics and Bioinformatics.

Little is known about the cause of idiopathic pulmonary fibrosis (IPF), a devastating disease that is characterized by progressive scarring of the lung tissue that affects a person’s ability to bre

Heart failure patients have a tendency to accumulate excess fluid in the body, which can lead to debilitating symptoms such as shortness of breath and swelling. Loop diuretic medication, aims to prevent accumulation of this fluid and is the cornerstone treatment for heart failure signs and symptoms. With more than six million Americans affected by heart failure, and about one million hospitalized every year, a new DCRI study called TRANSFORM-HF will directly compare two well-known diuretics – furosemide and torsemide – to determine which is the most effective.